Know Cancer

forgot password

A Phase 1-2, Open-Label Study of The X-Linked Inhibitor of Apoptosis (XIAP) Antisense AEG35156 in Combination With Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC)

Phase 1/Phase 2
18 Years
Not Enrolling
Advanced Hepatocellular Carcinoma

Thank you

Trial Information

A Phase 1-2, Open-Label Study of The X-Linked Inhibitor of Apoptosis (XIAP) Antisense AEG35156 in Combination With Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC)

Inclusion Criteria:

- HCC diagnosed by:

- Histology, or

- AASLD Criteria in which the diagnosis is made clinically in a patient with a
known hepatitis B or cirrhosis of other etiology has a liver mass of > 2cm with
typical features of HCC (i.e., hypervascular with washout in the portal/venous
phase) on a dynamic imaging study (contrast CT / USG / MRI) or alternatively if
the AFP is >200 ng/ml.

- The tumor is not suitable for curative treatment (resection / transplant / local
ablative therapies) or the patient is medically inoperable or refuses such treatment.

- At least one measurable lesion according to RECIST criteria.

- Age > 18 years.

- Life expectancy of greater than 12 weeks.

- ECOG performance status ≤ 2 (please refer to Appendix 1).

- Child-Pugh score A or B (please refer to Appendix 2).

- Adequate organ functions defined as:

- ANC ≥ 1.5 x 109/L

- Platelet count ≥ 75 x 109/L

- Creatinine ≤ 1.5 x ULN

- ALT or AST < 2.5 x ULN

- Total bilirubin < 50 μmol/L

- INR <1.7

- No encephalopathy clinically

- Normal ECG

- For women of child-producing potential, the use of effective contraceptive methods
during the study.

- Prior local therapy to tumor (e.g. surgery, RFA, PEI, chemo-embolization,
radiotherapy) is allowed provided that there is a target lesion not subjected to
local therapy and/or disease progression has been documented in the target lesion
subjected to local therapy. The treatment must be completed at least 4 weeks and
patient has recovered from all the acute toxicities of that treatment.

- For patients with hepatitis B, the patient must receive antiviral therapy prior to or
with registration.

Exclusion Criteria:

- Child-Pugh score C.

- Patients who have had prior systemic chemotherapy.

- Patients who have had any other cancer related therapy including radiotherapy within
4 weeks prior to entering the study.

- Patients receiving any other investigational agents concurrently.

- Patients with known brain metastases should be excluded from this clinical trial
because of their poor prognosis and because they often develop progressive neurologic
dysfunction that would confound the evaluation of neurologic and other adverse

- Patients who have peripheral neuropathy.

- Uncontrolled intercurrent disease such as, but not limited to, ongoing or active
infection or psychiatric illness/social situations that would limit compliance with
study requirements.

- Known bleeding diathesis.

- Pregnant or nursing women. NOTE: Women of child-bearing potential must agree to use
adequate contraception (sterile or surgically sterile; hormonal or barrier method of
birth control; or abstinence) prior to study entry and for the duration of study
participation. Should a woman become pregnant or suspect she is pregnant while
participating in this study, she should inform her treating physician immediately.

- Men who are unwilling to use acceptable forms of birth control when engaging in
sexual contact with women of child bearing potential.

- Active, uncontrolled bacterial, viral, or fungal infections, requiring systemic

- Serious nonmalignant disease that could compromise protocol objectives in the opinion
of the investigator and/or the sponsor.

- Patients who are currently receiving any other investigational agent. Subjects who
have used a previous antisense oligonucleotide in the last 90 days will be excluded.

- Unwillingness or inability to comply with procedures required in this protocol.

Type of Study:


Study Design:

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

To determine the recommended dose of AEG35156 in combination with sorafenib patients with advanced HCC

Outcome Description:

13 patients were enrolled into the phase 1 dose escalation part of the study. The recommended dose was determined to be 300 mg.

Outcome Time Frame:

12 months

Safety Issue:


Principal Investigator

Ann Shing Lee, MBChB(CUHK), FHKAM(Rad)

Investigator Role:

Principal Investigator

Investigator Affiliation:

Tuen Mun Hospital


Hong Kong: Department of Health

Study ID:




Start Date:

March 2009

Completion Date:

May 2011

Related Keywords:

  • Advanced Hepatocellular Carcinoma
  • Advanced Hepatocellular carcinoma
  • liver
  • cancer
  • antisense
  • sorafenib
  • Carcinoma
  • Carcinoma, Hepatocellular